NCT07007195 Smart Olfaction App to Reduce Relapse
| NCT ID | NCT07007195 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | University of Houston |
| Condition | Nicotine Dependence |
| Study Type | INTERVENTIONAL |
| Enrollment | 132 participants |
| Start Date | 2026-04-22 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 132 participants in total. It began in 2026-04-22 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The proposed project aims to refine and test a novel biobehavioral smoking cessation intervention that integrates the strategic application of olfactory stimulation to reduce cigarette craving with an established smartphone-based smoking cessation application. The specific aims of this study are: (1) refine the design and methodology of our olfactory stimulation delivery system (OSDS) and (2) compare, in a pilot randomized controlled trial (RCT), the effects of a smartphone based app for smoking cessation (Smart-T) with and without the OSDS on smoking cessation outcomes.
Eligibility Criteria
Inclusion Criteria: * At least 18 years of age * Ability to read, understand and speak English * Currently smoke at least 5 cigarettes daily for one year or longer * Do not currently smoke marijuana or currently smoke marijuana but willing to not smoke during the duration of the study * Did not use electronic cigarette or vaping device in the past 90 days * Have an active smartphone that is Apple or Android based * Have phone service including a data plan * Interested in downloading the study app onto their personal phone * Motivated to quit smoking * English literacy of 7th grade or higher, as indicated by a score of ≥ 4 on the Rapid Estimate of Adult Literacy in Medicine-Short Form (REALM-SF) * Biochemical verification of smoking status * Proof of smoking status at enrollment via photo of cigarettes * Presents a photo ID that matches the information on screener survey * Willing and able to complete study procedures * Willing to use NRT and quit smoking for 14 days (Phase I) or willing to use NRT and quit smoking for 13 weeks (Phase II) Exclusion Criteria: * Olfactory dysfunction including inability to smell, a very weak or distorted sense of smell, or sensitivity to odors * Report any allergies or negative reactions to odors/fragranced products * Being pregnant, breastfeeding, or planning to become pregnant within the next month * Report hypertension that is not under control * Have had a heart attack within the past two weeks * Those who participated in Phase I will not be eligible to participate in Phase II * Have a smartphone that is not compatible with the Insight mHealth platform * Report using electronic cigarette or vaping device in the past 90 days
Contact & Investigator
Lorra Garey, Ph.D.
PRINCIPAL INVESTIGATOR
University of Houston
Frequently Asked Questions
Who can join the NCT07007195 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Nicotine Dependence. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07007195 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07007195 currently recruiting?
Yes, NCT07007195 is actively recruiting participants. Contact the research team at llgarey@central.uh.edu for enrollment information.
Where is the NCT07007195 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT07007195 clinical trial?
NCT07007195 is sponsored by University of Houston. The principal investigator is Lorra Garey, Ph.D. at University of Houston. The trial plans to enroll 132 participants.